Prophylactic Medication for the Prevention of Endoscopic Recurrence in Crohn’s Disease: a Prospective Study Based on Clinical Risk StratificationJeanine Arkenbosch, Annemarie C. de Vries, Marijn C. Visschedijk et al.|Journal of Crohn s and Colitis|2022Cited by 31
Combined Clinical and Histopathological Risk Stratification for Prediction of (severe) Endoscopic Postoperative Recurrence in Patients with Crohn’s Disease after Ileocolic ResectionMichiel T. Bak, Lindsey Oudijk, Ariadne H.A.G. Ooms et al.|Annals of Surgery|2025Cited by 5
A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn’s Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI TrialReinier C A van Linschoten, Fenna M. Jansen, R Pauwels et al.|Digestive Diseases and Sciences|2024Cited by 2
Mo1804 IMAGING-BASED PREOPERATIVE BODY COMPOSITION IS ASSOCIATED WITH THE RISK OF POSTOPERATIVE COMPLICATIONS AND POSTOPERATIVE ENDOSCOPIC RECURRENCE IN PATIENTS WITH CROHN'S DISEASEMichiel T. Bak, Annemarie C. de Vries, Karlijn Demers et al.|Gastroenterology|2024Cited by 0
Su1849: LONG-TERM OUTCOMES OF EXTENDED VERSUS CONVENTIONAL ADALIMUMAB DOSE INTERVAL FOR PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: 3-YEAR FOLLOW-UP OF THE RANDOMIZED CONTROLLED LADI TRIALLisa M. van Lierop, Frank Hoentjen, F. A. R. Jansen et al.|Gastroenterology|2025Cited by 0